GLP-1 Receptor Agonists in Solid Tumour Therapy: Exploring Their Anticancer Potential and Underlying Molecular...

Area of Science:

• Oncology
• Pharmacology

Background:

• Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are established type 2 diabetes treatments.
• Emerging research explores GLP-1 RAs for their potential anticancer properties in various solid malignancies.

Purpose of the Study:

• To critically review the molecular mechanisms of GLP-1 RAs in cancer.
• To evaluate their antitumor activity and potential tumorigenic concerns.

Main Methods:

• Review of preclinical studies (in vitro and in vivo) on GLP-1 RAs in cancer.
• Analysis of molecular pathways modulated by GLP-1 RAs, including PI3K/Akt, PKA, and AMPK.
• Examination of effects on cancer cell proliferation, apoptosis, angiogenesis, and inflammation.

Main Results:

• Preclinical data indicate GLP-1 RAs possess antitumor activity, inhibiting tumor growth and metastasis.
• GLP-1 RAs modulate key signaling pathways and exert anti-inflammatory effects.
• Concerns regarding potential tumorigenic effects in specific cancer types persist.

Conclusions:

• GLP-1 RAs demonstrate preclinical antineoplastic potential through various molecular mechanisms.
• Further clinical investigation is essential to establish the therapeutic relevance of GLP-1 RAs in oncology.
• GLP-1 RAs may be considered as adjuncts in managing solid tumors.